News &amp; Updates

In adults with transfusion-dependent (TD*) α- or β-thalassaemia, mitapivat, a first-in-class, oral, allosteric activator of pyruvate kinase, significantly reduces transfusion burden, with durable responses up to 36 weeks, findings from the phase III ENERGIZE-T study have shown.

Mitapivat cuts transfusion burden in TD thalassaemia

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

Adding pembrolizumab to trastuzumab and chemotherapy significantly improves overall survival (OS) in patients with advanced unresectable or metastatic HER2+ gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and in those with PD-L1 CPS ≥1, according to the protocol-specified final OS analysis of the KEYNOTE-811 trial presented at ESMO Asia 2024.

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

New UC guideline endorses early use of advanced therapies

The American Gastroenterological Association (AGA), in an update to its living practice guideline, recommends the early use of advanced therapies for the pharmacological management of moderate-to-severe ulcerative colitis (UC) in adult outpatients.

New UC guideline endorses early use of advanced therapies

Hitting OS endpoint reaffirms frontline daratumumab-VCd as SoC for AL amyloidosis

The evidence supporting an upfront daratumumab-containing regimen as the SoC for AL amyloidosis is reaffirmed by the significant OS benefit demonstrated in the final analysis of ANDROMEDA

Hitting OS endpoint reaffirms frontline daratumumab-VCd as SoC for AL amyloidosis

Novel vaccine passes phase II trial in virally suppressed CHB

Therapeutic vaccination with ChAdOx1-HBV/MVA-HBV (VTP-300) has generated CD4+ and CD8+ cells and reduced HBsAg in a subset of chronic hepatitis B (CHB) patients with baseline values <100 IU/ml, as shown in a phase Ib/IIa trial. Moreover, a significant decrease in surface antigen occurs when the vaccine is combined with low-dose nivolumab.

Novel vaccine passes phase II trial in virally suppressed CHB

26 Dec 2024

Add-on eltrombopag RACEs to the frontline for aplastic anaemia treatment

26 Dec 2024 by

In the final 2-year analysis of the EBMT-SAAWP* RACE** study, the addition of eltrombopag to standard immunosuppressive treatment (IST) comprising horse antithymocyte globulin (hATG) plus cyclosporin A (CsA) improves long-term outcomes as frontline therapy for severe aplastic anaemia/very severe aplastic anaemia (SAA/vSAA).

Add-on eltrombopag RACEs to the frontline for aplastic anaemia treatment

Long-term nitrogen exposure linked to wider consequences

People exposed to nitrogen (NO2) in the long term are at risk of a range of diseases, including cardiovascular, respiratory, and musculoskeletal diseases, according to a study conducted in China.

Long-term nitrogen exposure linked to wider consequences

COPD patients at increased risk of CVD

25 Dec 2024 by

Patients with chronic obstructive pulmonary disease (COPD), especially those with concurrent chronic bronchitis and emphysema phenotypes, are prone to the development of cardiovascular disease (CVD), a recent study has shown.

COPD patients at increased risk of CVD

25 Dec 2024

What are the risk factors for MACE, malignancy in rheumatoid arthritis?

Factors such as male sex, older age, and prior X-ray examination are linked to an increased risk of major adverse cardiovascular events (MACE) and malignancies in patients with rheumatoid arthritis, according to a study from Japan.

What are the risk factors for MACE, malignancy in rheumatoid arthritis?

What’s new, what’s hot in diabetes management: Snippets from ATTD-ASIA

ATTD-ASIA 2024, held recently in Singapore, was a huge success, with nearly 800 delegates from 49 countries gracing the event. ATTD-Asia 2024 chair, Professor Moshe Phillip, said the event brought together top diabetes experts to ensure patients can access the latest technologies and treatments for diabetes. MIMS Doctor reports highlights and snippets from the conference.

What’s new, what’s hot in diabetes management: Snippets from ATTD-ASIA